Cardiovascular medicine
Research activity is centered on severe symptomatic aortic stenosis and its management in the setting of transcatheter aortic valve implantation (TAVI), with attention to post-procedural antiplatelet therapy and related cardiovascular outcomes.
- Aortic valve disease
- Transcatheter aortic valve implantation
- Post-TAVI antithrombotic treatment
The sponsor’s clinical interest includes balancing protection from thrombotic events with the risk of bleeding in older and high-risk cardiac populations.
Thrombotic and bleeding risk management
Funding is directed toward comparing ticagrelor and aspirin in the prevention of net adverse clinical events, reflecting a focus on both ischemic protection and hemorrhagic safety after valve intervention.
- Antiplatelet therapy
- Stroke prevention
- Bleeding complications
Clinical outcomes of interest include transient ischemic attack, myocardial infarction, and procedure-related vascular events.
Ischemic and vascular complications
The research portfolio addresses complications affecting the cerebrovascular, coronary, and peripheral arterial systems, including recurrent angina, valve thrombosis, claudication, and acute limb ischemia.
- Cerebrovascular events
- Coronary ischemia
- Peripheral arterial ischemia
These interests place emphasis on the broader vascular consequences associated with structural heart disease treatment.
Multicenter cardiovascular collaboration
Clinical research is conducted through a broad network of collaborating sites across multiple countries, supporting study activity in interventional cardiology and valvular heart disease.
- Multinational site collaboration
- Valvular intervention research
- Cardiovascular outcomes assessment
The sponsor’s functional identity as a Cardiovascular Research Unit is reflected in its concentration on post-procedural cardiac and vascular safety.
